2/12
09:46 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $29.00 price target on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $29.00 price target on the stock.
2/6
03:39 pm
mygn
Hannah Storm breaks down latest with NBA trade deadline, Luka Doncic and more [USA TODAY]
Low
Report
Hannah Storm breaks down latest with NBA trade deadline, Luka Doncic and more [USA TODAY]
2/6
08:30 am
mygn
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Low
Report
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
2/5
04:50 pm
mygn
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay [Yahoo! Finance]
Low
Report
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay [Yahoo! Finance]
2/5
04:15 pm
mygn
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
Low
Report
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
2/5
10:10 am
mygn
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration [Yahoo! Finance]
Low
Report
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration [Yahoo! Finance]
2/5
08:30 am
mygn
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Medium
Report
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
1/30
08:18 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $24.00 to $14.00. They now have a "neutral" rating on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $24.00 to $14.00. They now have a "neutral" rating on the stock.
1/29
08:30 am
mygn
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Low
Report
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
1/28
10:44 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $29.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $29.00 to $18.00. They now have a "buy" rating on the stock.
1/23
08:30 am
mygn
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
Low
Report
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
1/21
08:30 am
mygn
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Medium
Report
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
1/16
10:45 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "equal weight" rating re-affirmed by analysts at Stephens. They now have a $20.00 price target on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "equal weight" rating re-affirmed by analysts at Stephens. They now have a $20.00 price target on the stock.
1/15
09:15 am
mygn
Myriad Genetics expects Q4 revenues to be between $209M and $211M [Seeking Alpha]
Low
Report
Myriad Genetics expects Q4 revenues to be between $209M and $211M [Seeking Alpha]
1/15
08:30 am
mygn
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
Medium
Report
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
1/9
11:02 pm
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
1/9
04:30 pm
mygn
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
Low
Report
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
1/8
11:27 am
mygn
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
1/8
08:00 am
mygn
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
1/7
08:35 am
mygn
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay [Yahoo! Finance]
Medium
Report
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay [Yahoo! Finance]
1/7
08:00 am
mygn
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
Medium
Report
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
1/6
08:00 am
mygn
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
Medium
Report
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
12/31
04:52 pm
mygn
CIO Rashmi Kumar On Medtronic’s Path To Tech-Enabled Healthcare [Forbes]
Low
Report
CIO Rashmi Kumar On Medtronic’s Path To Tech-Enabled Healthcare [Forbes]
12/24
01:30 pm
mygn
Tempus AI Stock Plunges 28.9% in Three Months: What's Next? [Yahoo! Finance]
Neutral
Report
Tempus AI Stock Plunges 28.9% in Three Months: What's Next? [Yahoo! Finance]
12/24
06:18 am
mygn
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price [Yahoo! Finance]
Medium
Report
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price [Yahoo! Finance]